These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole. Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW; Clin Microbiol Infect; 2012 Jul; 18(7):E248-50. PubMed ID: 22540149 [TBL] [Abstract][Full Text] [Related]
5. Antifungal susceptibility of bloodstream yeasts isolated at a public children's hospital in Brazil: comparison of the Etest and the AFST-EUCAST microdilution method. Matsumoto FE; Dias AL; Melhem MS; Szeszs MW; Auler ME; Ruiz LS; Gonçalves da Silva E; Gandra RF; Paula CR Can J Microbiol; 2007 Dec; 53(12):1300-6. PubMed ID: 18059562 [TBL] [Abstract][Full Text] [Related]
6. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. Espinel-Ingroff A; Barchiesi F; Cuenca-Estrella M; Pfaller MA; Rinaldi M; Rodriguez-Tudela JL; Verweij PE J Clin Microbiol; 2005 Aug; 43(8):3884-9. PubMed ID: 16081926 [TBL] [Abstract][Full Text] [Related]
7. EUCAST technical note on voriconazole and Aspergillus spp. Hope WW; Cuenca-Estrella M; Lass-Flörl C; Arendrup MC; Clin Microbiol Infect; 2013 Jun; 19(6):E278-80. PubMed ID: 23413937 [TBL] [Abstract][Full Text] [Related]
8. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Arendrup MC; Friberg N; Mares M; Kahlmeter G; Meletiadis J; Guinea J; Clin Microbiol Infect; 2020 Nov; 26(11):1464-1472. PubMed ID: 32562861 [TBL] [Abstract][Full Text] [Related]
9. EUCAST breakpoints for antifungals. Rodríguez-Tudela JL; Arendrup MC; Cuenca-Estrella M; Donnelly JP; Lass-Flörl C Drug News Perspect; 2010 Mar; 23(2):93-7. PubMed ID: 20369073 [TBL] [Abstract][Full Text] [Related]
10. EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents. Arendrup MC; Meletiadis J; Mouton JW; Guinea J; Cuenca-Estrella M; Lagrou K; Howard SJ; Clin Microbiol Infect; 2016 Jun; 22(6):571.e1-4. PubMed ID: 26851656 [TBL] [Abstract][Full Text] [Related]
11. EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole. Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW; Mycoses; 2014 Jun; 57(6):377-9. PubMed ID: 24417759 [TBL] [Abstract][Full Text] [Related]
12. In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections. Beredaki MI; Arendrup MC; Mouton JW; Meletiadis J Int J Antimicrob Agents; 2021 Mar; 57(3):106291. PubMed ID: 33508404 [TBL] [Abstract][Full Text] [Related]
13. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Arendrup MC; Cuenca-Estrella M; Lass-Flörl C; Hope WW Drug Resist Updat; 2013 Dec; 16(6):81-95. PubMed ID: 24618110 [TBL] [Abstract][Full Text] [Related]
14. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp]. Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462 [TBL] [Abstract][Full Text] [Related]
15. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. Sóczó G; Kardos G; McNicholas PM; Balogh E; Gergely L; Varga I; Kelentey B; Majoros L J Antimicrob Chemother; 2007 Nov; 60(5):1004-9. PubMed ID: 17875607 [TBL] [Abstract][Full Text] [Related]
16. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Pfaller MA; Andes D; Arendrup MC; Diekema DJ; Espinel-Ingroff A; Alexander BD; Brown SD; Chaturvedi V; Fowler CL; Ghannoum MA; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Walsh TJ Diagn Microbiol Infect Dis; 2011 Jul; 70(3):330-43. PubMed ID: 21546199 [TBL] [Abstract][Full Text] [Related]
17. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Bedini A; Venturelli C; Mussini C; Guaraldi G; Codeluppi M; Borghi V; Rumpianesi F; Barchiesi F; Esposito R Clin Microbiol Infect; 2006 Jan; 12(1):75-80. PubMed ID: 16460550 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the broth microdilution (BMD) method of the European Committee on Antimicrobial Susceptibility Testing and the Clinical Laboratory Standards Institute BMD method for non-Candida albicans and non-C. tropicalis bloodstream isolates from eleven tertiary hospitals in São Paulo state, Brazil. Purisco SU; Martins MA; Szeszs MW; Castro e Silva DM; Pukinskas SR; Bonfietti LX; Baez AA; Melhem MS FEMS Yeast Res; 2012 Dec; 12(8):890-6. PubMed ID: 22883021 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN J Clin Microbiol; 2001 Nov; 39(11):3952-4. PubMed ID: 11682513 [TBL] [Abstract][Full Text] [Related]
20. Susceptibility of Candida species and various moulds to antimycotic drugs: use of epidemiological cutoff values according to EUCAST and CLSI in an 8-year survey. Rambach G; Oberhauser H; Speth C; Lass-Flörl C Med Mycol; 2011 Nov; 49(8):856-63. PubMed ID: 21619497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]